IMV - IMV's vaccine candidate potentially effective against COVID-19 shares up 16%

IMV (IMV) rises 16% premarket after providing an update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection. The Company has successfully completed preclinical safety, GLP toxicology as well as immunogenicity and challenge studies confirming a favorable safety profile and potential for the long duration of antibody titers and protection against SARS-CoV-2.Additional supporting evidence favoring DPX-COVID-19 includes T cell response and “natural” immunity in convalescent plasma against the targeted epitope peptides in the DPX-COVID-19 formulation.Vaccine candidate is stable at 2°C to 8°C and room temperature for at least 3 months.IMV has collaborated with a global manufacturing partner and initiated transfer and scale-up activities of DPX-COVID-19 in India and Europe to produce several hundred million doses.The Company is planning to conduct complementary preclinical studies including testing on new variants and will provide an update in Q1 2021 on its revised clinical plan.

For further details see:

IMV's vaccine candidate potentially effective against COVID-19, shares up 16%